GlobeNewswire

Aprea Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update
13/05/2026
Oversubscribed $30 million private placement closed, with proceeds expected to support ongoing development of APR-1051 Two partial responses observed with continued encouraging tolerability in the ongoing Phase 1 dose [...]
Voyager ASGCT Late Breaker: Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 3-Month GLP Toxicology Data; Clinical Trial in Alzheimer’s Disease Expected H2 2026
13/05/2026
- VY1706 IND application process on track for Q2 2026; clinical entry expected H2 2026 - - Data from eight ASGCT presentations highlight Voyager’s continued innovation in gene therapy - LEXINGTON, Mass., May 13, 2026 ( [...]
Zenas BioPharma Reports First Quarter 2026 Financial Results and Provides Corporate Update
13/05/2026
– Obexelimab marketing applications for the treatment of IgG4-RD on-target for submission to the FDA this quarter and the EMA in H2 2026 based on the Phase 3 INDIGO IgG4-RD trial results – – Obexelimab Phase 3 INDIGO [...]
Zymeworks Announces Participation in Upcoming Investor Conferences
13/05/2026
VANCOUVER, British Columbia, May 13, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, [...]
NVision Expands from Quantum Sensing to Quantum Computing to Accelerate Discovery and Validation of New Therapies
13/05/2026
$55 Million Series B to Advance Quantum for Healthcare ULM, Germany, May 13, 2026 (GLOBE NEWSWIRE) -- NVision , a leader in quantum technologies for healthcare, today announced a $55 million Series B financing round [...]
HepaRegeniX to Present Interim Phase 1b Data for Darizmetinib (HRX215) in a Late-Breaking Oral Presentation at the European Association for the Study of the Liver (EASL) Congress 2026
13/05/2026
Tuebingen , Germany, May 13 , 202 6 – HepaRegeniX GmbH (“HepaRegeniX”), a clinical-stage biotech company advancing novel therapies for acute and chronic liver diseases, announces that its abstract highlighting clinical [...]
Anaveon Appoints Thomas P. Mathers as Chair of the Board of Directors
13/05/2026
BASEL, Switzerland, May 13, 2026 (GLOBE NEWSWIRE) -- Anaveon, a late-stage biotechnology company pioneering precision biologics to reprogram the immune system for the treatment of autoimmune and inflammatory diseases, [...]
Inventiva to Present Abstracts at the EASL Congress 2026
13/05/2026
Daix (France), New York City (New York, United States) , May 13, 2026 – Inventiva (Euronext Paris and NASDAQ: IVA ) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development [...]
Inventiva présentera plusieurs abstracts lors de l’EASL Congress 2026
13/05/2026
Daix (France), New York City (New York, Etats-Unis), le 13 mai 2026 – Inventiva (Euronext Paris et NASDAQ: IVA ) (« Inventiva » ou la « Société »), société biopharmaceutique au stade clinique spécialisée dans le [...]
Fortis Life Sciences attribue la subvention à la découverte AbNano® VHH Discovery 2026 à Deliver Biosciences pour la recherche sur l’administration ciblée de médicaments
13/05/2026
Le programme de subvention élargit l’accès aux technologies d’anticorps à domaine unique avancées, afin de soutenir la recherche et le développement des traitements de nouvelle génération BOSTON et LONDRES, 13 mai 2026 [...]
Aligos Therapeutics Announces Ten Abstracts Accepted for Presentation at the EASL Congress 2026
13/05/2026
SOUTH SAN FRANCISCO, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies [...]
Fangzhou Showcases “AI+H2H” Chronic Disease Service Innovations at the National Intelligent Medicine Conference
13/05/2026
WUHAN, China, May 13, 2026 (GLOBE NEWSWIRE) -- Fangzhou Inc. (“Fangzhou” or the “Company”) (HKEX: 06086), a leading provider of AI‑driven Internet healthcare solutions, participated in the 2026 National Medical Industry [...]
Assembly Biosciences to Present Topline Phase 1a Data on Hepatitis Delta Virus Entry Inhibitor ABI-6250 at the EASL Congress 2026
13/05/2026
SOUTH SAN FRANCISCO, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today announced [...]
Wegovy® pill delivered 21.6% weight loss in early responders and doubled mobility improvement, according to new Novo Nordisk data at ECO2026
13/05/2026
Almost a third of adults taking Wegovy ® pill (oral semaglutide 25 mg) were early responders to treatment, achieving an average of 13.2% weight loss after four months and 21.6% weight loss at the end of the OASIS 4 [...]
Bavarian Nordic Announces Interim Results for the First Three Months of 2026
13/05/2026
COPENHAGEN, Denmark, May 13, 2026 – Bavarian Nordic A/S (OMX: BAVA) announced today its interim financial results and business progress for the first three months of 2026. Revenue for the first three months was DKK 1, [...]
IBA introduces AdaPTinsight XR, the next generation of CBCT imaging for image-guided proton therapy
13/05/2026
Proton therapy CBCT imaging solution across Proteus ® Portfolio providing clarity and confidence in IGPT Louvain-la-Neuve, Belgium, May 13, 2026 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle [...]
IBA lance AdaPTinsight XR, la nouvelle génération d’imagerie CBCT pour la protonthérapie guidée par l’image
13/05/2026
Une solution d’imagerie CBCT pour les systèmes de protonthérapie Proteus ® offrant une visibilité claire qui permet des traitements IGPT en toute confiance Louvain-la-Neuve, Belgique, le 13 mai 2026 – IBA (Ion Beam [...]
Valneva Reports First Quarter 2026 Financial Results and Provides Corporate Updates
13/05/2026
Total product sales of €30.5 million Cash position of €105.3 million as of end March 2026, excluding proceeds from successful reserved offering completed in April 2026 1 Program launched in April to further reduce [...]
Valneva publie ses résultats financiers audités et consolidés pour le premier trimestre 2026
13/05/2026
Ventes de produits de 30,5 millions d’euros Position de trésorerie de 105,3 millions d’euros à fin mars 2026, hors produit de la levée de fonds réservée réalisée avec succès en avril 2026 1 Lancement, en avril 2026, d’ [...]

Pages

Other news

Test 2

Lorem ipsum

Test 1

Lorem upsum